Shares of NovoCure Ltd. (NASDAQ:NVCR) saw unusually-strong trading volume on Friday . Approximately 883,600 shares traded hands during trading, an increase of 99% from the previous session’s volume of 445,093 shares.The stock last traded at $7.37 and had previously closed at $8.09.

Several equities analysts have recently commented on NVCR shares. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of NovoCure in a research report on Tuesday, April 5th. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Barclays PLC reduced their price target on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Friday. Deutsche Bank AG reduced their price target on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday. Finally, JMP Securities cut their target price on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $21.43.

The firm’s market cap is $635.58 million. The firm’s 50 day moving average price is $11.24 and its 200-day moving average price is $12.76.

NovoCure (NASDAQ:NVCR) last released its earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.11. The business had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $15.90 million. Equities analysts forecast that NovoCure Ltd. will post ($1.46) EPS for the current year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the transaction, the chief operating officer now owns 324,084 shares of the company’s stock, valued at approximately $3,966,788.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. Hartline Investment Corp purchased a new position in NovoCure during the fourth quarter worth $1,143,000. Century Capital Management LLC purchased a new position in NovoCure during the fourth quarter worth $2,970,000. Finally, Morgan Stanley purchased a new position in NovoCure during the fourth quarter worth $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.